They suggested a personalised follow‐up, as in patients with variants in TERT or RTEL1 genes, who are more prone to develop HCC or extra‐hepatic organ failure (lung or bone marrow), [30, 31] targeted therapy, as for iron in patients with hemochromatosis and replacement therapy for the one with CESD, or additional specialist referrals. This evidence concerns the gene TERT and hepatocellular carcinoma.